Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Ginkgo Bioworks Holdings, Inc. stock logo
DNA
Ginkgo Bioworks
$0.93
-5.5%
$1.08
$0.74
$2.55
$2.01B1.4228.37 million shs48.43 million shs
Guardant Health, Inc. stock logo
GH
Guardant Health
$18.82
-1.5%
$18.36
$15.81
$41.06
$2.29B0.921.83 million shs1.40 million shs
RCT
Rochester Resources
C$0.03
+25.0%
C$0.02
C$0.02
C$0.04
C$1.18M1.7716,876 shs5,000 shs
20 Stocks to Sell Now Cover

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Ginkgo Bioworks Holdings, Inc. stock logo
DNA
Ginkgo Bioworks
+3.43%-0.20%-8.54%-23.43%-22.22%
Guardant Health, Inc. stock logo
GH
Guardant Health
+1.17%+5.00%+8.34%-15.22%-19.24%
RCT
Rochester Resources
0.00%0.00%0.00%+25.00%-28.57%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Ginkgo Bioworks Holdings, Inc. stock logo
DNA
Ginkgo Bioworks
1.5141 of 5 stars
3.01.00.00.01.83.30.6
Guardant Health, Inc. stock logo
GH
Guardant Health
4.5125 of 5 stars
4.41.00.04.61.93.30.6
RCT
Rochester Resources
N/AN/AN/AN/AN/AN/AN/AN/A

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Ginkgo Bioworks Holdings, Inc. stock logo
DNA
Ginkgo Bioworks
2.00
Hold$2.20135.55% Upside
Guardant Health, Inc. stock logo
GH
Guardant Health
2.83
Moderate Buy$37.70100.32% Upside
RCT
Rochester Resources
N/AN/AN/AN/A

Current Analyst Ratings

Latest GH, RCT, EHG, DNA, and SPO Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/29/2024
Guardant Health, Inc. stock logo
GH
Guardant Health
Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$45.00 ➝ $30.00
4/24/2024
Guardant Health, Inc. stock logo
GH
Guardant Health
Craig Hallum
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$28.00
4/15/2024
Guardant Health, Inc. stock logo
GH
Guardant Health
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$32.00 ➝ $28.00
4/5/2024
Guardant Health, Inc. stock logo
GH
Guardant Health
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingNeutral
3/1/2024
Ginkgo Bioworks Holdings, Inc. stock logo
DNA
Ginkgo Bioworks
TD Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$7.00 ➝ $3.00
2/26/2024
Guardant Health, Inc. stock logo
GH
Guardant Health
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$40.00 ➝ $30.00
2/23/2024
Guardant Health, Inc. stock logo
GH
Guardant Health
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$60.00 ➝ $45.00
2/23/2024
Guardant Health, Inc. stock logo
GH
Guardant Health
Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$50.00 ➝ $45.00
(Data available from 5/7/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Ginkgo Bioworks Holdings, Inc. stock logo
DNA
Ginkgo Bioworks
$251.46M7.99N/AN/A$0.55 per share1.70
Guardant Health, Inc. stock logo
GH
Guardant Health
$563.95M4.06N/AN/A$1.34 per share14.04
RCT
Rochester Resources
C$13.18M0.09C$0.00 per share7.50C($0.69) per share-0.04

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Ginkgo Bioworks Holdings, Inc. stock logo
DNA
Ginkgo Bioworks
-$892.87M-$0.47N/AN/AN/A-355.08%-48.23%-31.35%5/9/2024 (Confirmed)
Guardant Health, Inc. stock logo
GH
Guardant Health
-$479.45M-$4.28N/AN/AN/A-85.02%-301.94%-27.65%5/9/2024 (Confirmed)
RCT
Rochester Resources
-C$5.54M-C$0.10N/AN/A-42.02%N/A-34.80%9/26/2024 (Estimated)

Latest GH, RCT, EHG, DNA, and SPO Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/9/2024N/A
Ginkgo Bioworks Holdings, Inc. stock logo
DNA
Ginkgo Bioworks
-$0.08N/A+$0.08N/AN/AN/A  
5/9/2024N/A
Guardant Health, Inc. stock logo
GH
Guardant Health
-$0.7220N/A+$0.7220N/AN/AN/A  
2/29/202412/31/2023
Ginkgo Bioworks Holdings, Inc. stock logo
DNA
Ginkgo Bioworks
-$0.09-$0.10-$0.01-$0.07$40.37 million$34.76 million    
2/22/2024Q4 2023
Guardant Health, Inc. stock logo
GH
Guardant Health
-$0.93-$1.58-$0.65-$1.58$151.71 million$155.05 million

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Ginkgo Bioworks Holdings, Inc. stock logo
DNA
Ginkgo Bioworks
N/AN/AN/AN/AN/A
Guardant Health, Inc. stock logo
GH
Guardant Health
N/AN/AN/AN/AN/A
RCT
Rochester Resources
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Ginkgo Bioworks Holdings, Inc. stock logo
DNA
Ginkgo Bioworks
N/A
6.11
6.11
Guardant Health, Inc. stock logo
GH
Guardant Health
7.18
6.54
6.24
RCT
Rochester Resources
N/A
0.24
0.09

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Ginkgo Bioworks Holdings, Inc. stock logo
DNA
Ginkgo Bioworks
78.63%
Guardant Health, Inc. stock logo
GH
Guardant Health
92.60%
RCT
Rochester Resources
2.85%

Insider Ownership

CompanyInsider Ownership
Ginkgo Bioworks Holdings, Inc. stock logo
DNA
Ginkgo Bioworks
15.05%
Guardant Health, Inc. stock logo
GH
Guardant Health
6.20%
RCT
Rochester Resources
58.99%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Ginkgo Bioworks Holdings, Inc. stock logo
DNA
Ginkgo Bioworks
1,2182.15 billion1.83 billionOptionable
Guardant Health, Inc. stock logo
GH
Guardant Health
1,779121.71 million114.17 millionNot Optionable
RCT
Rochester Resources
N/A47.14 millionN/ANot Optionable

GH, RCT, EHG, DNA, and SPO Headlines

No headlines for this company have been tracked by MarketBeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

All Headlines

Company Descriptions

Ginkgo Bioworks logo

Ginkgo Bioworks

NYSE:DNA
Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. It serves pharma and biotech, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.
Guardant Health logo

Guardant Health

NASDAQ:GH
Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers. It offers Shield Test; Guardant Reveal Test for adjuvant treatment selection in early-stage cancer patients; Smart Liquid Biopsy Platform; and Guardant Galaxy, an AI-backed digital pathology platform that helps improve cancer biomarker detection. In addition, the company offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, technologies licensing, and kits fulfillment. The company has a collaboration agreement with Illumina, Inc. for the sharing of specimen samples to advance cancer research. The company was incorporated in 2011 and is headquartered in Palo Alto, California.

Rochester Resources

CVE:RCT
Rochester Resources Ltd., a junior natural resource company, engages in the acquisition, exploration, and development of mineral properties in Mexico. It primarily explores for gold and silver deposits. The company holds 100% interest in the Mina Real property that consists of 11 mining concessions and one mineral claim covering approximately 21,367.42 hectares; and the San Francisco property, which includes twelve mining concessions covering an area of 18,125.05 hectares. It also has an agreement to acquire a 70% interest in the Santa Fe property that comprises one mining concession covering approximately 3,852.66 hectares. The company was incorporated in 1989 and is headquartered in Vancouver, Canada.